Surmodics, Inc. (SRDX)

Market Cap	591.16M
Revenue (ttm)	142.96M
Net Income (ttm)	13.50M
Shares Out	14.27M
EPS (ttm)	0.96
PE Ratio	43.17
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	205,375
Open	41.77
Previous Close	41.55
Day's Range	41.30 - 41.77
52-Week Range	25.17 - 42.44
Beta	1.18
Analysts	Hold
Price Target	43.00 (+3.76%)
Earnings Date	Aug 5, 2024

About SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 4, 1998
• Employees: 376
• Stock Exchange: NASDAQ
• Ticker Symbol: SRDX

Financial Performance

In 2023, Surmodics's revenue was $132.58 million, an increase of 32.65% compared to the previous year's $99.95 million. Losses were -$1.54 million, -94.37% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for SRDX stock is "Hold." The 12-month stock price forecast is $43.0, which is an increase of 3.76% from the latest price.

Price Target

$43.0

(3.76% upside)

Analyst Consensus: Hold